Literature DB >> 26405022

Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE.

M M das Chagas Medeiros1, M Campos Bezerra2, F N Holanda Ferreira Braga2, M R Melo da Justa Feijão2, A C Rodrigues Gois2, V C do Rosário Rebouças2, T M Amorim Zaranza de Carvalho2, L N Solon Carvalho2, Át Mendes Ribeiro2.   

Abstract

The clinical expression of systemic lupus erythematosus (SLE) is influenced by genetic and environmental factors and therefore varies between ethnicities. Information on the epidemiology of SLE in Brazil is scarce and practically limited to studies conducted in socioeconomically developed regions (South and Southeast). The objective of this study was to describe the clinical and immunological aspects and outcome of a cohort of patients with SLE treated at a university hospital in northeastern Brazil and compare patterns related to age at onset: childhood (cSLE), adult (aSLE), and late (lSLE). A random sample of 414 records (women: 93.5%) were reviewed. The mean age at SLE onset and the mean disease duration were 28.9 ± 10.9 years and 10.2 ± 6.6 years, respectively. Most patients had aSLE (n = 338; 81.6%), followed by cSLE (n = 60; 14.5%) and lSLE (n = 16; 3.9%). The female/male ratio was 6.5:1 in cSLE and 16.8:1 in aSLE; in lSLE, all patients were female (p = 0.05). During follow-up, the cSLE group presented higher rates of nephritis (70% vs. 52.9% vs. 12.5%; p = 0.0001) and leuko/lymphopenia (61.7% vs. 43.8% vs. 56.2%; p = 0.02). No significant differences were found for anti-dsDNA, anti-Sm, and antiphospholipid antibodies. Treatment with immunosuppressants was significantly more common, and higher doses of prednisone were used, in cSLE. The prevalence of cardiovascular diseases were more frequent in lSLE (p = 0.03). No significant differences were found between the three groups with regard to mean damage accrual (SDI), remission, and mortality. Although cSLE presented higher rates of nephritis and leuko/lymphopenia, more frequent use of immunosuppressants and higher prednisone doses than aSLE and lSLE, the three groups did not differ significantly with regard to damage accrual, remission, and mortality.
© The Author(s) 2015.

Entities:  

Keywords:  Adult-onset SLE; childhood-onset SLE; late-onset SLE; systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 26405022     DOI: 10.1177/0961203315606983

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus.

Authors:  Rafael Hennemann Sassi; Jordana Vaz Hendler; Giovana Fagundes Piccoli; Andrese Aline Gasparin; Rafael Mendonça da Silva Chakr; João Carlos Tavares Brenol; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2016-11-17       Impact factor: 2.980

2.  Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality.

Authors:  Alimohammad Fatemi; Mohammad Matinfar; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2016-12-23       Impact factor: 2.980

3.  Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study.

Authors:  Lihui Wen; Ziyan Chen; Ziyi Jin; Wenyou Pan; Lin Liu; Min Wu; Fuwan Ding; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Xuebing Feng; Jun Liang; Huayong Zhang; Lingyun Sun
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

4.  Very Late-Onset Systemic Lupus Erythematosus as Unusual Cause of Reversible Functional and Cognitive Impairments in an Octogenarian Patient.

Authors:  Stéphanie de Montjoye; Benoit Boland; Jacqueline Van Raemdonck; Frédéric A Houssiau
Journal:  Eur J Case Rep Intern Med       Date:  2020-05-07

5.  Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Jennifer L Medlin; Karen E Hansen; Sara S McCoy; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2018-01-31       Impact factor: 5.532

6.  Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature.

Authors:  Rakesh Kumar Pilania; Deepti Suri; Ankur Kumar Jindal; Narender Kumar; Avinash Sharma; Praveen Sharma; Sandesh Guleria; Amit Rawat; Jasmina Ahluwalia; Surjit Singh
Journal:  Rheumatol Int       Date:  2018-08-11       Impact factor: 3.580

7.  Mast cells in the kidney biopsies of pediatric patients with lupus nephritis.

Authors:  Stéfany Silva Santos; Carolina Marques Ramos; Maria Luiza Gonçalves Dos Reis Monteiro; Juliana Reis Machado; Marlene Antônia Dos Reis; Rosana Rosa Miranda Corrêa; Laura Penna Rocha
Journal:  J Bras Nefrol       Date:  2020-01-31

8.  Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.

Authors:  Linlin Sheng; Xiuqin Cao; Shuhong Chi; Jing Wu; Huihui Xing; Huiyu Liu; Zhiwei Yang
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

9.  Clinicopathological findings and outcome of lupus nephritis in Tunisian children: a review of 43 patients.

Authors:  Hela Jebali; Meriam Hajji; Lamia Rais; Fethi Ben Hamida; Soumaya Beji; Mohammed Karim Zouaghi
Journal:  Pan Afr Med J       Date:  2017-06-30

10.  Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients-a multicenter retrospective cohort.

Authors:  Basma M Medhat; Mervat Essam Behiry; Nesreen Sobhy; Yomna Farag; Huda Marzouk; Noha Mostafa; Iman Khalifa; Marwa Elkhalifa; Basma M Eissa; Eman Hassan ElSayed Hassan
Journal:  Clin Rheumatol       Date:  2019-11-22       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.